Genetic Signatures Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Allison Rossiter

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	1.1yrs
Promedio de permanencia en la Junta Directiva	3yrs

Actualizaciones recientes de la dirección

Recent updates

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Mar 08

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Nov 14

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Oct 10

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Jun 29

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Feb 28

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

Feb 25

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

Feb 07

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Jan 17

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

Dec 27

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

Dec 06

CEO

Allison Rossiter

less than a year

Permanencia

Ms. Allison Rossiter serves as Chief Executive Officer at Genetic Signatures Limited from 2024. She has extensive healthcare experience, with a distinguished career at Roche Diagnostics. Her international...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Karl Pechmann	CFO, COO & Company Secretary	1.4yrs	AU$353.57k	sin datos
Michael Aicher	Executive Director of US Operations & Executive Director	10.8yrs	AU$182.63k	0.28% A$ 452.0k
Allison Rossiter	Chief Executive Officer	less than a year	sin datos	sin datos
Christopher Abbott	Founder & Chairman Emeritus	no data	sin datos	0% A$ 0
Rebecca Abbatantuono	Global Head of People & Culture	less than a year	sin datos	sin datos
Neralie Coulston	Global Head of Regulatory Affairs	2yrs	sin datos	sin datos
Rohan Baker	Head of Research & Acting QC Manager	less than a year	sin datos	sin datos

1.1yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de GSS no se considera experimentado ( 1.1 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Aicher	Executive Director of US Operations & Executive Director	10.8yrs	AU$182.63k	0.28% A$ 452.0k
Christopher Abbott	Founder & Chairman Emeritus	no data	sin datos	0% A$ 0
Jenny Harry	Non-Executive Director	less than a year	sin datos	sin datos
Caroline Waldron	Non-Executive Director	2.5yrs	AU$109.15k	0.0099% A$ 15.8k
Nickolaos Samaras	Independent Non-Executive Chairman	16.8yrs	AU$133.20k	1.1% A$ 1.7m
Anne Lockwood	Non-Executive Director	less than a year	sin datos	sin datos
Neil Gunn	Non-Executive Director	3.6yrs	AU$941.46k	sin datos

3.0yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de GSS se considera experimentada (3 años de antigüedad promedio).

Genetic Signatures Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Genetic Signatures Limited, Annual General Meeting, Nov 20, 2024

Genetic Signatures Limited Announces Changes to Board of Directors

Director recently bought AU$59k worth of stock

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Less than half of directors are independent

Recent updates

Genetic Signatures Limited, Annual General Meeting, Nov 20, 2024

New minor risk - Market cap size

Consensus EPS estimates fall by 60%

Full year 2024 earnings: EPS misses analyst expectations

Genetic Signatures Limited Announces Changes to Board of Directors

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

New major risk - Shareholder dilution

Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen™ Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Director recently bought AU$59k worth of stock

New minor risk - Profitability

Consensus revenue estimates fall by 28%

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.979326 million.

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Consensus revenue estimates decrease by 31%

New minor risk - Shareholder dilution

Genetic Signatures Limited has filed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Price target decreased by 20% to AU$0.90

Now 20% undervalued after recent price drop

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Now 21% undervalued after recent price drop

Full year 2023 earnings released: AU$0.098 loss per share (vs AU$0.021 profit in FY 2022)

New minor risk - Financial data availability

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Consensus EPS estimates fall by 37%

Price target increased by 8.0% to AU$0.95

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.033 profit in 1H 2022)

Less than half of directors are independent

Price target decreased to AU$0.90

Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Full year 2022 earnings released: EPS: AU$0.021 (vs AU$0.012 in FY 2021)

Genetic Signatures Limited Announces Clinical Trial Recruitment Completed for US Enteric Kit

Genetic Signatures Limited Announces Appointment of Caroline Waldron as New Non-Executive Director

Price target decreased to AU$1.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues exceed analyst expectations

Genetic Signatures Limited Announces 3base® SARS-CoV-2 diagnostic kit registered by TGA for saliva samples

Full year 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to AU$2.20

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Consensus revenue estimates fall to AU$28.0m

New 90-day low: AU$1.58

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

First half 2021 earnings released: EPS AU$0.032 (vs AU$0.021 loss in 1H 2020)

Revenue beats expectations, earnings disappoint

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: AU$1.65

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

New 90-day low - AU$1.95

Full year earnings released - AU$0.016 loss per share

New 90-day high - AU$2.62

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad